



# TU684 Feasibility and Efficacy of Transcutaneous Vagus Nerve Stimulation for Knee Osteoarthritis Pain



THE UNIVERSITY OF TEXAS AT EL PASO

Kosaku Aoyagi<sup>1</sup>, Elias Rivas<sup>1</sup>, Roxanna Shababi<sup>1</sup>, Levi Johnson<sup>1</sup>, Michael LaValley<sup>2</sup>, Robert Edwards<sup>3</sup>, Julia Lechuga<sup>1</sup>, Tuhina Neogi<sup>2</sup>

<sup>1</sup>University of Texas at El Paso, El Paso; <sup>2</sup>Boston University, Boston; <sup>3</sup>Brigham and Women's Hospital/Harvard Medical School, Boston

## Background

- Central pain mechanisms are major contributors to knee osteoarthritis (OA) pain
- Diminished parasympathetic function has been reported in knee OA, and a major contributor to central pain mechanisms
- Transcutaneous auricular vagus nerve stimulation (tVNS) aims to improve parasympathetic function
- However, tVNS has not yet been used as a pain-relieving treatment in knee OA

## Objective

To test the safety and preliminary efficacy of tVNS on knee OA pain

## Methods

**Design:** A pilot trial with a single study visit

**Sample:** People with Knee OA



**tVNS:** A 60-minute, strong & comfortable intensity (up to 15mA)

**Outcomes** were assessed at baseline, immediately after, and 15 minutes after tVNS

**Knee Pain:** a 0-10 numeric rating scale during a 20-meter walk; minimally clinically important improvement (MCII)  $\geq 2/10$



## Parasympathetic Function

Heart rate variability high-frequency power


- HR monitor & validated app
- Higher high-frequency power indicates greater parasympathetic function

tVNS may be an innovative non-pharmacological treatment for knee OA pain by modulating parasympathetic function, which needs to be confirmed in large clinical trials

## Results

Participant Characteristics	Age mean (SD)	Women n (%)	BMI mean (SD)	Hispanic n (%)	Depression n (%)	Anxiety n (%)	Poor sleep n (%)
N=30	55 (7.8)	20 (67)	33.1 (6.2)	25 (83)	7 (23)	10 (33)	20 (67)





## Mean Differences (95% CI), Before and After tVNS



**Safety and Feasibility**

- All completed the tVNS without difficulty
- 28/30 had no side effects
- 2 experienced either momentary nausea or dizziness

Knee Pain: 11/30 (37%) exceeded MCII



## Methods, continued

### Central Pain Mechanisms

#### Pressure Pain Threshold



- Algometer at the wrist
- Lower PPT → greater central sensitivity

#### Temporal Summation



- 10-second train at 1Hz with a weighted probe
- An increase in pain → central sensitization

#### Conditioned Pain Modulation



A ratio PPT2:PPT1  $\leq 1$  → Inefficient CPM

- Analytic Approach: Linear Mixed Models
- Changes in the outcomes after tVNS

## Discussion

- A 60-minute tVNS was safe and feasible
- tVNS successfully engaged parasympathetic function in knee OA
- tVNS improved knee OA pain without local intervention
- It may suggest improvement of central pain mechanisms through modulating parasympathetic function
- Need a large fully powered trial to confirm its effectiveness on knee OA pain

### Limitations:

- No control group
- A single tVNS session
- Most of the sample was people with Hispanic background